National Psoriasis Foundation launches Seal of Recognition program
PORTLAND, Ore. — The National Psoriasis Foundation has introduced a Seal of Recognition that will be touted on select products that dermatology experts deem effective in relieving disease symptoms.
"Improving the quality of life for people with psoriasis and psoriatic arthritis is the reason the foundation has launched its seal program," said Eric Kimble, National Psoriasis Foundation board of trustees member and head of the corporate review committee for the seal. "The seal will help consumers identify, from a maze of available products, items that could provide a benefit for psoriatic diseases."
Five products for scalp psoriasis made by Neutrogena and one product by Alva-Amco Pharmacal are the first to feature the seal, the foundation said. To qualify for the recognition, products are reviewed by a panel of dermatology experts who make sure the items meet the following criteria, including:
Products that hydrate the skin, reduce redness, reduce joint pain and/or provide aid for people with psoriatic arthritis;
Non-irritating products; and
Products that can be used along with prescription remedies.
The panel also reviews the products’ ingredients and safety, toxicity and formulation data.
To learn more about the program, click here.
FDA exploring how to expand eligible Rx-to-OTC switches by utilizing pharmacy
SILVER SPRING, Md. — The Food and Drug Administration on Tuesday announced it will hold a public hearing on March 22 and 23 to discuss how technology can expand which drug products can be switched from prescription to over-the-counter status.
"These conditions of safe use would be specific to the drug product and might require sale in certain pre-defined healthcare settings, such as a pharmacy," the agency stated in the Federal Register. "For example, some conditions of safe use could be designed to assist patients in self-selection of an appropriate medication or provide for follow-up monitoring during continued use. The conditions of use could include requiring pharmacist intervention to ensure appropriate nonprescription use."
Other innovative technologies could include diagnostics approved for use in a pharmacy setting, the agency added. "For example, some diseases or conditions might require confirmation of a diagnosis or routine monitoring using a diagnostic test (e.g., a blood test for cholesterol levels or liver function) that could be available in a pharmacy."
Pfizer acquires Alacer
NEW YORK — One of the world’s largest pharmaceutical companies has acquired the maker and distributor of Emergen-C products.
Pfizer on Monday announced its acquisition of Alacer, a privately held company best known for its vitamin C supplement products. Financial terms of the transaction were not disclosed, but Pfizer did note that the deal would complement its Consumer Healthcare division.
“We are very pleased that the Emergen-C family of products will become part of Pfizer’s portfolio. We expect that our global network and deep expertise in dietary supplements combined with our desire to provide consumers with high-quality products will make Emergen-C more accessible than it has ever been before,” Pfizer Consumer Healthcare president Paul Sturman said. “Emergen-C products add to and greatly complement our market-leading dietary supplement portfolio.”